AU5438299A
(en)
*
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
PT1169038E
(pt)
|
1999-04-15 |
2012-10-26 |
Bristol Myers Squibb Co |
Inibidores cíclicos da proteína tirosina cinase
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
ATE396978T1
(de)
|
1999-10-07 |
2008-06-15 |
Amgen Inc |
Triazin-kinase-hemmer
|
HUP0301117A3
(en)
|
2000-02-17 |
2004-01-28 |
Amgen Inc Thousand Oaks |
Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
|
GB0004890D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
*
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
AU783981C
(en)
*
|
2000-05-08 |
2007-05-03 |
Janssen Pharmaceutica N.V. |
HIV replication inhibitors
|
EP1282607B1
(en)
|
2000-05-08 |
2015-11-11 |
Janssen Pharmaceutica NV |
Prodrugs of hiv replication inhibiting pyrimidines
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
EP1313729B1
(en)
|
2000-08-17 |
2007-03-21 |
Lumera Corporation |
Design and synthesis of thiophene derived nlo materials for electro-optic applications
|
GB0021726D0
(en)
*
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6610677B2
(en)
|
2000-09-15 |
2003-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
JP4105948B2
(ja)
*
|
2000-09-15 |
2008-06-25 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼインヒビターとして有用なピラゾール化合物
|
EP1698627A1
(en)
*
|
2000-09-15 |
2006-09-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US20020137755A1
(en)
|
2000-12-04 |
2002-09-26 |
Bilodeau Mark T. |
Tyrosine kinase inhibitors
|
US7122544B2
(en)
|
2000-12-06 |
2006-10-17 |
Signal Pharmaceuticals, Llc |
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
|
US7129242B2
(en)
|
2000-12-06 |
2006-10-31 |
Signal Pharmaceuticals, Llc |
Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
|
CA2433018A1
(en)
|
2000-12-21 |
2002-06-27 |
Joel C. Barrish |
Thiazolyl inhibitors of tec family tyrosine kinases
|
AU2006201228B2
(en)
*
|
2000-12-21 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole Compounds Useful as Protein Kinase Inhibitors
|
KR100909665B1
(ko)
*
|
2000-12-21 |
2009-07-29 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
|
MXPA03005696A
(es)
*
|
2000-12-21 |
2003-10-06 |
Glaxo Group Ltd |
Pirimidinaminas como moduladores de angiogenesis.
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
GB0107901D0
(en)
*
|
2001-03-29 |
2001-05-23 |
Cyclacel Ltd |
Anti-cancer compounds
|
WO2002096888A1
(de)
*
|
2001-05-29 |
2002-12-05 |
Schering Aktiengesellschaft |
Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
|
DE10127581A1
(de)
*
|
2001-05-29 |
2003-01-02 |
Schering Ag |
CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
WO2002102313A2
(en)
*
|
2001-06-19 |
2002-12-27 |
Bristol-Myers Squibb Company |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
JP4510442B2
(ja)
*
|
2001-06-26 |
2010-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
TNF−α発現のN−ヘテロ環インヒビター
|
US7115617B2
(en)
*
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
WO2003026665A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
EP1453516A2
(de)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
DE50212771D1
(de)
|
2001-10-17 |
2008-10-23 |
Boehringer Ingelheim Pharma |
Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
AU2003202263A1
(en)
|
2002-01-10 |
2003-07-30 |
Bayer Healthcare Ag |
Roh-kinase inhibitors
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
CA2473910C
(en)
|
2002-01-23 |
2011-03-15 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
TW200302728A
(en)
|
2002-02-01 |
2003-08-16 |
Novartis Ag |
Substituted amines as IgE inhibitors
|
RU2004126671A
(ru)
*
|
2002-02-06 |
2005-04-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
|
EP1472233A1
(en)
*
|
2002-02-08 |
2004-11-03 |
SmithKline Beecham Corporation |
Pyrimidine compounds
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
US7351729B2
(en)
|
2002-03-08 |
2008-04-01 |
Signal Pharmaceuticals, Llc |
JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
EP1490354A1
(en)
|
2002-03-09 |
2004-12-29 |
Astrazeneca AB |
4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
|
DE10212100A1
(de)
*
|
2002-03-11 |
2003-10-23 |
Schering Ag |
CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
EP1483260A1
(de)
*
|
2002-03-11 |
2004-12-08 |
Schering Aktiengesellschaft |
Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
|
US7288547B2
(en)
|
2002-03-11 |
2007-10-30 |
Schering Ag |
CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
|
WO2003078427A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazines as inhibitors of protein kinases
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US7176310B1
(en)
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
EP1515964A1
(en)
*
|
2002-06-14 |
2005-03-23 |
ALTANA Pharma AG |
Substituted diaminopyrimidines
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
US7449456B2
(en)
*
|
2002-06-28 |
2008-11-11 |
Astellas Pharma, Inc. |
Diaminopyrimidinecarboxamide derivative
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
KR101297924B1
(ko)
*
|
2002-07-29 |
2013-08-20 |
리겔 파마슈티칼스, 인크. |
2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
|
ATE451104T1
(de)
*
|
2002-07-29 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
|
EP2130541A3
(en)
*
|
2002-07-29 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
DE10239042A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Schering Ag |
Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
RS20060097A
(en)
*
|
2002-12-20 |
2008-11-28 |
Pfizer Products Inc., |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7157455B2
(en)
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
CL2004000306A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
|
JP4634367B2
(ja)
*
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
PT1626714E
(pt)
|
2003-05-20 |
2007-08-24 |
Bayer Pharmaceuticals Corp |
Diarilureias para doenças mediadas por pdgfr
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
CA2530281C
(en)
*
|
2003-07-24 |
2013-02-12 |
Bayer Pharmaceuticals Corporation |
Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
|
PL1656372T3
(pl)
|
2003-07-30 |
2013-08-30 |
Rigel Pharmaceuticals Inc |
Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
|
US20050113398A1
(en)
|
2003-08-07 |
2005-05-26 |
Ankush Argade |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
CA2533320A1
(en)
*
|
2003-08-15 |
2006-02-24 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
DE10349423A1
(de)
|
2003-10-16 |
2005-06-16 |
Schering Ag |
Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
DE602004022187D1
(de)
|
2003-10-17 |
2009-09-03 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
|
AU2004297235A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
JP2007513967A
(ja)
*
|
2003-12-11 |
2007-05-31 |
セラヴァンス, インコーポレーテッド |
変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
WO2005080350A1
(en)
*
|
2004-02-23 |
2005-09-01 |
Glaxo Group Limited |
Pyrimidine derivatives as cannabinoid receptor modulators
|
WO2005095382A1
(ja)
*
|
2004-03-30 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
抗腫瘍剤
|
DE602005024382D1
(de)
*
|
2004-04-13 |
2010-12-09 |
Astellas Pharma Inc |
Polycyclische pyrimidine als kaliumionenkanal-modulatoren
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
BRPI0510980A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina para o tratamento do crescimento anormal de células
|
BRPI0510963A
(pt)
|
2004-05-14 |
2007-11-20 |
Pfizer Prod Inc |
derivados pirimidina para o tratamento do crescimento anormal de células
|
MXPA06011658A
(es)
|
2004-05-14 |
2006-12-14 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
CA2566531A1
(en)
*
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
US7405220B2
(en)
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
US7521457B2
(en)
*
|
2004-08-20 |
2009-04-21 |
Boehringer Ingelheim International Gmbh |
Pyrimidines as PLK inhibitors
|
GB0419160D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
TW200626574A
(en)
*
|
2004-09-30 |
2006-08-01 |
Tibotec Pharm Ltd |
HIV inhibiting 5-heterocyclyl pyrimidines
|
TW200626560A
(en)
*
|
2004-09-30 |
2006-08-01 |
Tibotec Pharm Ltd |
HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
|
TW200626561A
(en)
*
|
2004-09-30 |
2006-08-01 |
Tibotec Pharm Ltd |
HIV inhibiting 5-substituted pyrimidines
|
GB2420559B
(en)
*
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
CA2587427A1
(en)
|
2004-11-17 |
2006-05-26 |
Miikana Therapeutics, Inc. |
Kinase inhibitors
|
US7557207B2
(en)
|
2004-11-24 |
2009-07-07 |
Rigel Pharmaceuticals, Inc. |
Spiro 2,4-pyrimidinediamine compounds and their uses
|
MY169441A
(en)
*
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
WO2006064251A1
(en)
*
|
2004-12-17 |
2006-06-22 |
Astrazeneca Ab |
4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
|
ATE519759T1
(de)
|
2004-12-30 |
2011-08-15 |
Exelixis Inc |
Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
|
MX2007008434A
(es)
|
2005-01-19 |
2007-07-25 |
Squibb Bristol Myers Co |
Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
|
BRPI0606318B8
(pt)
|
2005-01-19 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, composição, e, uso de um composto
|
AU2006215386B2
(en)
|
2005-02-16 |
2009-06-11 |
Astrazeneca Ab |
Chemical compounds
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
JP2008540436A
(ja)
*
|
2005-05-03 |
2008-11-20 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jakキナーゼインヒビターおよびそれらの使用
|
BRPI0610184A2
(pt)
*
|
2005-05-16 |
2012-09-25 |
Astrazeneca Ab |
composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
JP2009501711A
(ja)
*
|
2005-07-11 |
2009-01-22 |
サノフイ−アベンテイス |
新規2,4−ジアニリノピリミジン誘導体、その調製、医薬、医薬組成物としての、特に、ikk阻害剤としてのそれらの使用
|
FR2888239B1
(fr)
*
|
2005-07-11 |
2008-05-09 |
Sanofi Aventis Sa |
Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
|
AU2006274733B2
(en)
*
|
2005-07-30 |
2010-09-16 |
Astrazeneca Ab |
Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
|
AU2006279376B2
(en)
*
|
2005-08-18 |
2011-04-14 |
Vertex Pharmaceuticals Incoporated |
Pyrazine kinase inhibitors
|
WO2007032445A1
(ja)
*
|
2005-09-16 |
2007-03-22 |
Kyowa Hakko Kogyo Co., Ltd. |
タンパク質キナーゼ阻害剤
|
US7745428B2
(en)
|
2005-09-30 |
2010-06-29 |
Astrazeneca Ab |
Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
|
ES2535854T3
(es)
|
2005-09-30 |
2015-05-18 |
Miikana Therapeutics, Inc. |
Compuestos de pirazol sustituidos
|
GB0520958D0
(en)
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
EP2388259A1
(en)
|
2005-10-28 |
2011-11-23 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
AU2012230091B2
(en)
*
|
2005-11-01 |
2015-04-23 |
Impact Biomedicines, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US7528143B2
(en)
*
|
2005-11-01 |
2009-05-05 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
ES2533241T3
(es)
*
|
2005-11-03 |
2015-04-08 |
Vertex Pharmaceuticals Incorporated |
Aminopirimidinas útiles como inhibidores de cinasas
|
US7705009B2
(en)
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
JP4332590B2
(ja)
|
2005-12-21 |
2009-09-16 |
ファイザー・プロダクツ・インク |
異常細胞増殖を治療するためのピリミジン誘導体
|
DE102005062742A1
(de)
*
|
2005-12-22 |
2007-06-28 |
Bayer Schering Pharma Ag |
Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
|
CA2633980A1
(en)
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
EP2004632B1
(en)
*
|
2006-03-30 |
2014-03-12 |
Janssen R&D Ireland |
Hiv inhibiting 5-amido substituted pyrimidines
|
PE20120006A1
(es)
*
|
2006-05-15 |
2012-02-02 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
DE602007012363D1
(de)
|
2006-10-19 |
2011-03-17 |
Rigel Pharmaceuticals Inc |
2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
|
EP2222647B1
(en)
|
2006-10-23 |
2015-08-05 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
|
DE602007004750D1
(de)
*
|
2006-11-02 |
2010-03-25 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
|
SI2091918T1
(sl)
|
2006-12-08 |
2015-01-30 |
Irm Llc |
Spojine in sestavki kot inhibitorji protein-kinaze
|
MX2009006081A
(es)
*
|
2006-12-08 |
2009-06-17 |
Irmc Llc |
Compuestos y composiciones como inhibidores de cinasa de proteina.
|
JP2010513567A
(ja)
*
|
2006-12-19 |
2010-04-30 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼの阻害剤として有用なアミノピリミジン
|
CN101573343B
(zh)
|
2006-12-29 |
2016-02-24 |
爱尔兰詹森科学公司 |
抑制人免疫缺陷病毒的6-取代的嘧啶
|
CA2923637C
(en)
*
|
2006-12-29 |
2018-10-02 |
Janssen Sciences Ireland Uc |
Hiv inhibiting 5,6-substituted pyrimidines
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
NZ579446A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
MX2009009592A
(es)
|
2007-03-09 |
2009-11-10 |
Vertex Pharma |
Aminopiridinas utiles como inhibidores de proteinas cinasas.
|
NZ579485A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
JP2010523700A
(ja)
|
2007-04-13 |
2010-07-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼインヒビターとして有用なアミノピリミジン
|
CN101801959A
(zh)
*
|
2007-05-02 |
2010-08-11 |
沃泰克斯药物股份有限公司 |
可用作激酶抑制剂的氨基嘧啶类化合物
|
MX2009011810A
(es)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
AU2008247595A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
CN101687852A
(zh)
*
|
2007-05-24 |
2010-03-31 |
沃泰克斯药物股份有限公司 |
可用作激酶抑制剂的噻唑类和吡唑类化合物
|
AU2008282156B2
(en)
*
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
SI2252300T1
(sl)
*
|
2008-02-22 |
2017-04-26 |
Rigel Pharmaceuticals, Inc. |
Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
KR101773313B1
(ko)
|
2008-04-16 |
2017-08-31 |
포톨라 파마슈티컬스, 인코포레이티드 |
syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
|
NZ589315A
(en)
|
2008-04-16 |
2012-11-30 |
Portola Pharm Inc |
2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
|
BRPI0910668A2
(pt)
|
2008-04-22 |
2019-09-24 |
Portola Pharmaceutiacals Inc |
inibidores de proteína quinases
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
SG10201510696RA
(en)
|
2008-06-27 |
2016-01-28 |
Celgene Avilomics Res Inc |
Heteroaryl compounds and uses thereof
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP2323622A1
(en)
*
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
AR073760A1
(es)
*
|
2008-10-03 |
2010-12-01 |
Astrazeneca Ab |
Derivados heterociclicos y metodos de uso de los mismos
|
EP2179992A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
EP2179991A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
EP2179993A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
PL2399910T3
(pl)
|
2009-02-13 |
2014-09-30 |
Shionogi & Co |
Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
|
DE102009001438A1
(de)
|
2009-03-10 |
2010-09-16 |
Bayer Schering Pharma Aktiengesellschaft |
Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
DE102009015070A1
(de)
|
2009-03-30 |
2010-10-14 |
Bayer Schering Pharma Aktiengesellschaft |
Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
WO2011017178A1
(en)
*
|
2009-07-28 |
2011-02-10 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2011019943A1
(en)
*
|
2009-08-12 |
2011-02-17 |
Poniard Pharmaceuticals, Inc. |
Method of promoting apoptosis and inhibiting metastasis
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
WO2011065800A2
(ko)
*
|
2009-11-30 |
2011-06-03 |
주식회사 오스코텍 |
피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
|
DE102010014426A1
(de)
|
2010-04-01 |
2011-10-06 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
|
DE102010014427A1
(de)
|
2010-04-01 |
2011-10-06 |
Bayer Schering Pharma Aktiengesellschaft |
Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
WO2012006081A1
(en)
|
2010-06-29 |
2012-01-12 |
Poniard Pharmaceuticals, Inc. |
Oral formulation of kinase inhibitors
|
NZ604801A
(en)
|
2010-06-30 |
2015-03-27 |
Verastem Inc |
Synthesis and use of focal adhesion kinase inhibitors
|
RU2565073C2
(ru)
|
2010-08-10 |
2015-10-20 |
Сионоги Энд Ко., Лтд. |
Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью
|
US9212130B2
(en)
|
2010-08-10 |
2015-12-15 |
Shionogi & Co., Ltd. |
Heterocyclic derivative and pharmaceutical composition comprising the same
|
CN103096716B
(zh)
|
2010-08-10 |
2016-03-02 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐
|
WO2012061415A1
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
WO2012061428A2
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
BR112013010564B1
(pt)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
Compostos heterocíclicos e composições compreendendo os mesmos
|
CN103282352B
(zh)
|
2010-11-01 |
2016-08-10 |
波托拉医药品公司 |
作为syk调节剂的苯甲酰胺类和烟酰胺类
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
TW201325593A
(zh)
|
2011-10-28 |
2013-07-01 |
Celgene Avilomics Res Inc |
治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
JP6124351B2
(ja)
|
2012-02-09 |
2017-05-10 |
塩野義製薬株式会社 |
複素環および炭素環誘導体
|
SG11201405692UA
(en)
|
2012-03-15 |
2014-10-30 |
Celgene Avilomics Res Inc |
Salts of an epidermal growth factor receptor kinase inhibitor
|
WO2013138495A1
(en)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
JP2015510910A
(ja)
|
2012-03-21 |
2015-04-13 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
特定の腫瘍の処置のための、(rs)−s−シクロプロピル−s−(4−{[4−{[(1r,2r)−2−ヒドロキシ−1−メチルプロピル]オキシ}−5−(トリフルオロメチル)ピリミジン−2−イル]アミノ}フェニル)スルホキシミドの使用
|
EP2850067B1
(en)
|
2012-05-18 |
2017-08-16 |
Sumitomo Dainippon Pharma Co., Ltd. |
Carboxylic acid compounds
|
AU2013266438B2
(en)
*
|
2012-05-22 |
2017-09-07 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
CN104903301B
(zh)
*
|
2012-11-08 |
2017-08-29 |
百时美施贵宝公司 |
可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
|
US9771330B2
(en)
*
|
2012-11-27 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN103059030B
(zh)
*
|
2012-12-28 |
2015-04-29 |
北京师范大学 |
一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
|
WO2014124230A2
(en)
|
2013-02-08 |
2014-08-14 |
Celgene Avilomics Research, Inc. |
Erk inhibitors and uses thereof
|
US9346802B2
(en)
|
2013-03-15 |
2016-05-24 |
Epizyme, Inc. |
CARM1 inhibitors and uses thereof
|
US9718816B2
(en)
|
2013-03-15 |
2017-08-01 |
Epizyme, Inc. |
1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
|
MX2015012803A
(es)
|
2013-03-15 |
2016-08-19 |
Epizyme Inc |
Inhibidores de la carm1 y usos de los mismos.
|
WO2014173815A1
(en)
|
2013-04-23 |
2014-10-30 |
Bayer Pharma Aktiengesellschaft |
Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
|
CN103333119A
(zh)
*
|
2013-05-28 |
2013-10-02 |
中国药科大学 |
1,2-二氢-6-甲基-4-取代氨基-5-嘧啶羧酸类化合物及其制备方法和用途
|
TWI637949B
(zh)
|
2013-06-14 |
2018-10-11 |
塩野義製藥股份有限公司 |
胺基三衍生物及含有其等之醫藥組合物
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
PL3193611T3
(pl)
*
|
2014-09-17 |
2021-10-04 |
Celgene Car Llc |
Inhibitory mk2 i ich zastosowania
|
AU2016274576A1
(en)
|
2015-06-11 |
2017-12-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
p62-ZZ chemical inhibitor
|
CN106588885B
(zh)
*
|
2016-11-10 |
2019-03-19 |
浙江大学 |
2-取代芳环-嘧啶类衍生物及制备和应用
|
CN107903256B
(zh)
*
|
2017-11-29 |
2019-11-15 |
南方医科大学 |
一种含取代噻唑的2,4-二氨基嘧啶及其应用
|
KR20190108079A
(ko)
*
|
2018-03-13 |
2019-09-23 |
보로노이바이오 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
WO2019177374A1
(ko)
*
|
2018-03-13 |
2019-09-19 |
포로노이바이오 주식회사 |
2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
|
CA3145864A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
CN112390760B
(zh)
*
|
2020-10-15 |
2022-07-29 |
北京师范大学 |
靶向fak的化合物及其制备方法和应用
|
CN117043151A
(zh)
*
|
2021-12-13 |
2023-11-10 |
希格生科(深圳)有限公司 |
嘧啶或吡啶类衍生物及其医药用途
|
KR20230155351A
(ko)
*
|
2022-05-03 |
2023-11-10 |
한국화학연구원 |
5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
CN115677595B
(zh)
*
|
2022-10-26 |
2024-06-14 |
江苏睿实生物科技有限公司 |
一种2,4,5-三氯嘧啶的制备方法
|